Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 24, 2007

Averion Expands CRO Services into Brazil

  • Averion and Biocancer, two clinical research organizations (CROs), will jointly market and contract complementary services to biotechnology, pharmaceutical, and medical device companies.

    Biocancer is based in Brazil and focuses on oncology. “This agreement expands our reach to South America, providing us with access to leading clinical sites and large patient populations,” points out Philip Lavin, Ph.D., Averion's CEO. “We plan to continue building on our international oncology CRO offering through strategic partnerships and acquisitions.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »